The effects and mechanisms of combination of sodium-dependent glucose cotransporter inhibitor and canagliflozin (CA) and dipeptidyl peptidase-4 inhibitor and teneligliptin (TE) on non-diabetic NASH progression were examined. The gene discussed is SLC5A11; the disease is metabolic dysfunction-associated steatohepatitis.